MedTrace Logo

Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails

NCT00641433 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2008-03-24

No results posted yet for this study

Summary

This study's purpose is to prospectively determine whether topical therapy with an oxidized regenerated cellulose collagen-silver compound is more effective than the current standard of topical antibiotic therapy for care following the removal of an ingrown toenail. Eighty adult patients with ingrown toenails will be recruited. Each patient will randomly be assigned to apply either topical silver sulfadiazine cream (standard antibiotic) or the novel collagen-silver compound to their nail bed daily, following removal of the ingrown portion of nail. Patients will return for follow up visits weekly, until healing has occurred or twelve weeks have passed. Healing will be defined as resolution of drainage and inflammatory changes surrounding the nail border.

Conditions

  • Ingrown Nail

Interventions

DEVICE

oxidized regenerated cellulose collagen-silver

Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.

DRUG

topical silver sulfadiazine cream

Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.

Sponsors & Collaborators

  • Rosalind Franklin University of Medicine and Science

    lead OTHER

Principal Investigators

  • David G Armstrong, DPM, PhD · Rosalind Franklin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641433 on ClinicalTrials.gov